Research Progress and Perspectives of Antibody-drug Conjugates Targeting Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) remains a significant global health burden, and there is an urgent need for new treatment options. Trophoblast cell surface antigen-2 (TROP-2), a target closely associated with NSCLC prognosis, has become a research hotspot in recent years. Notably, TROP-2-targeted...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2024-10-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2024.101.25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141919931924480 |
|---|---|
| author | Jingyan XU Jiaqi LIU Shiqi MEI Qing ZHOU |
| author_facet | Jingyan XU Jiaqi LIU Shiqi MEI Qing ZHOU |
| author_sort | Jingyan XU |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) remains a significant global health burden, and there is an urgent need for new treatment options. Trophoblast cell surface antigen-2 (TROP-2), a target closely associated with NSCLC prognosis, has become a research hotspot in recent years. Notably, TROP-2-targeted antibody-drug conjugates (ADCs) have made groundbreaking advances in NSCLC therapy. Clinical studies have demonstrated that certain TROP-2 ADCs can significantly improve progression-free survival in previously treated patients with advanced or metastatic NSCLC, regardless of the presence of actionable genomic alterations. These agents have shown promising potential in both frontline and subsequent treatment settings. In terms of safety, while adverse effects affecting the hematologic, respiratory, and gastrointestinal systems are generally manageable, close clinical monitoring and timely management are still required. In conclusion, TROP-2 ADCs hold great promise in the treatment of NSCLC. |
| format | Article |
| id | doaj-art-aeba8ebfdbad4cc38ffa039fcc4c43f5 |
| institution | Kabale University |
| issn | 1009-3419 1999-6187 |
| language | zho |
| publishDate | 2024-10-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj-art-aeba8ebfdbad4cc38ffa039fcc4c43f52024-12-04T02:42:05ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872024-10-01271076377610.3779/j.issn.1009-3419.2024.101.25Research Progress and Perspectives of Antibody-drug Conjugates Targeting
Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung CancerJingyan XU0Jiaqi LIU1Shiqi MEI2Qing ZHOU3Guangdong Provincial Institute of Lung Cancer, Guangdong Provincial People's Hospital Affiliated to Southern Medical University, Guangdong Academy of Medical Sciences, Guangzhou 510080, ChinaGuangdong Provincial Institute of Lung Cancer, Guangdong Provincial People's Hospital Affiliated to Southern Medical University, Guangdong Academy of Medical Sciences, Guangzhou 510080, ChinaGuangdong Provincial Institute of Lung Cancer, Guangdong Provincial People's Hospital Affiliated to Southern Medical University, Guangdong Academy of Medical Sciences, Guangzhou 510080, ChinaGuangdong Provincial Institute of Lung Cancer, Guangdong Provincial People's Hospital Affiliated to Southern Medical University, Guangdong Academy of Medical Sciences, Guangzhou 510080, ChinaNon-small cell lung cancer (NSCLC) remains a significant global health burden, and there is an urgent need for new treatment options. Trophoblast cell surface antigen-2 (TROP-2), a target closely associated with NSCLC prognosis, has become a research hotspot in recent years. Notably, TROP-2-targeted antibody-drug conjugates (ADCs) have made groundbreaking advances in NSCLC therapy. Clinical studies have demonstrated that certain TROP-2 ADCs can significantly improve progression-free survival in previously treated patients with advanced or metastatic NSCLC, regardless of the presence of actionable genomic alterations. These agents have shown promising potential in both frontline and subsequent treatment settings. In terms of safety, while adverse effects affecting the hematologic, respiratory, and gastrointestinal systems are generally manageable, close clinical monitoring and timely management are still required. In conclusion, TROP-2 ADCs hold great promise in the treatment of NSCLC.http://dx.doi.org/10.3779/j.issn.1009-3419.2024.101.25lung neoplasmsactionable genomic alterationsantibody-drug conjugatestrophoblast cell surface antigen-2drug therapy |
| spellingShingle | Jingyan XU Jiaqi LIU Shiqi MEI Qing ZHOU Research Progress and Perspectives of Antibody-drug Conjugates Targeting Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer Chinese Journal of Lung Cancer lung neoplasms actionable genomic alterations antibody-drug conjugates trophoblast cell surface antigen-2 drug therapy |
| title | Research Progress and Perspectives of Antibody-drug Conjugates Targeting
Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer |
| title_full | Research Progress and Perspectives of Antibody-drug Conjugates Targeting
Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer |
| title_fullStr | Research Progress and Perspectives of Antibody-drug Conjugates Targeting
Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer |
| title_full_unstemmed | Research Progress and Perspectives of Antibody-drug Conjugates Targeting
Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer |
| title_short | Research Progress and Perspectives of Antibody-drug Conjugates Targeting
Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer |
| title_sort | research progress and perspectives of antibody drug conjugates targeting
trophoblast cell surface antigen 2 in advanced non small cell lung cancer |
| topic | lung neoplasms actionable genomic alterations antibody-drug conjugates trophoblast cell surface antigen-2 drug therapy |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2024.101.25 |
| work_keys_str_mv | AT jingyanxu researchprogressandperspectivesofantibodydrugconjugatestargetingtrophoblastcellsurfaceantigen2inadvancednonsmallcelllungcancer AT jiaqiliu researchprogressandperspectivesofantibodydrugconjugatestargetingtrophoblastcellsurfaceantigen2inadvancednonsmallcelllungcancer AT shiqimei researchprogressandperspectivesofantibodydrugconjugatestargetingtrophoblastcellsurfaceantigen2inadvancednonsmallcelllungcancer AT qingzhou researchprogressandperspectivesofantibodydrugconjugatestargetingtrophoblastcellsurfaceantigen2inadvancednonsmallcelllungcancer |